Skip to main content

Table 3a Risk factors for CMV and BKV viremia. Analyses were performed using Cox regression proportional hazards analysis. Covariates with a p < 0.100 were included in multivariate analyses

From: Transplant centers’ prophylaxis and monitoring strategies: a key determinant of current herpes and polyomavirus incidences – results from the DZIF kidney transplant cohort

 

CMV

BKV

 

Univariate

Multivariate

Univariate

Multivariate

 

HR

95%-CI

p

HR

95%-CI

p

HR

95%-CI

p

HR

95%-CI

p

Baseline data

            

Age (years)

0.998

0.987;1.010

0.765

   

1.007

0.995;1.020

0.268

   

Male gender

1.028

0.729;1.448

0.867

   

1.577

1.071;2.321

0.021

1.446

0.958;2.184

0.079

Deceased donor

2.004

1.340;2.997

< 0.001

2.258

1.441;3.539

< 0.001

1.119

0.773:1.618

0.552

   

ESP

0.720

0.415;1.249

0.243

   

0.654

0.361;1.184

0.161

   

Body mass index (kg/m2)

1.000

0.964;1.037

0.981

   

0.990

0.951;1.030

0.603

   

Previous transplantation

0.983

0.629;1.535

0.939

   

1.181

0.759:1.838

0.462

   

Pancreas-kidney

1.707

0.945;3.083

0.076

1.449

0.755;3.2.781

0.162

0.523

0.193;1.416

0.202

   

AB0i

0.692

0.306;1.569

0.378

   

0.750

0.331;1.702

0.492

   

CMV D+/R-

3.047

2.169;4.280

< 0.001

2.396

1.620;3.544

< 0.001

1.318

0.888;1.957

0.170

   

CMV R+

0.961

0.690;1.339

0.815

   

0.712

0.506;1.004

0.053

0.759

0.525;1.098

0.143

CMV D+

2.525

1.715;3.718

< 0.001

1.367

0.825;2.265

0.226

1.006

0.712;1.423

0.972

   

CMV prophylaxis1

2.815

1.648;4.807

< 0.001

1.607

0.836;3.090

0.155

0.841

0.573;1.233

0.375

   

Age class donor2

1.040

0.985;1.098

0.153

   

1.038

0.982;1.097

0.190

   

Delayed graft function3

1.272

0.859;1.884

0.230

   

0.824

0.517;1.315

0.418

   

Initial immunosuppression

Conditioning treatment4

1.493

1.064;2.094

0.020

1.500

0.856;2.630

0.157

1.041

0.716;1.513

0.833

   

Plasmapheresis

1.658

1.103;2.492

0.016

1.472

0.824;2.630

0.192

1.303

0.824;2.050

0.258

   

Thymoglobuline vs. BSX

1.620

1.103;2.380

0.014

0.907

0.513;1.605

0.737

1.209

0.782;1.869

0.392

   

Tacrolimus vs. Csa

1.210

0.771;1.897

0.407

   

1.640

0.968;2.778

0.066

1.726

1.016;2.934

0.044

Other events within first year posttransplantation

BPAR

1.760

1.162;2.658

0.007

0.998

0.560;1.776

0.994

0.738

0.407;1.340

0.319

   

TCMR

2.831

1.704;4.703

< 0.001

3.030

1.451;6.325

0.003

0.803

0.296;2.179

0.666

   

Bacterial infection

1.546

1.108;2.155

0.010

1.298

[0.919;1.833]

0.139

0.891

0.284;2.802

0.844

   

Fungal infection

1.585

0.699;3.592

0.270

   

0.927

0.641;1.343

0.690

   

Renal function 3 months after transplantation

eGFR in ml/min/1.73m2

0.998

0.989;1.006

0.573

   

0.978

0.969;0.987

< 0.001

0.977

0.968;0.987

< 0.001

  1. Abbreviations: CMV = Cytomegalovirus, BKV = BK-virus, ESP = Eurotransplant Senior Program, BSX = Basiliximab, Csa = Ciclosporine A, BPAR = biopsy proven acute rejection, TCMR = T-cell-mediated rejection, eGFR = estimated glomerular filtration rate, D+/-=Donor positive/negative, R+/-=Recipient positive/negative; HR = Hazard ratio, 95%-CI = 95%-confidence-interval
  2. 1 Valganciclovir, 2 In 5-year intervals, 3 Need for hemodialysis within the first 7 days post-transplantation, 4 Rituximab, immunadsorption, plasmapheresis or thymoglo for induction therapy;
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us